Medtronic will market Itamar's sleep apnea Dx products to some U.S. patients; NeuroMetrix rolls out second-generation pain management device;

@FierceMedDev: Teleflex's vascular system gains pivotal FDA clearance--the product comes from a previous M&A deal. More | Follow @FierceMedDev

@MarkHFierce: Mela Sciences' 2013 financials show how tough a relaunch of its skin cancer Dx tool will be. Story | Follow @MarkHFierce

@MichaelGFierce: SynapDx, Broad Institute align to make autism Dx with next-gen sequencing. Item | Follow @MichaelGFierce

@EmilyWFierce: Evidence of world's oldest case of metastatic cancer found in a skeleton in the Sudan. Article | Follow @EmilyWFierce

> Medtronic ($MDT) will market Itamar Medical's sleep apnea diagnostic products to atrial fibrillation patients in the U.S. Story

> NeuroMetrix ($NURO) of Waltham, MA, said it is rolling out the first shipments of its second-generation wearable pain management device. Release

> CeloNova BioSciences said it won FDA approval to begin an IDE trial for its new coronary stent system, which is designed to use a nano-coating technology that helps the artery heal faster and reduce the need for long-term blood-thinning medication. Release

> Digirad, a Georgia maker of imaging devices, snatched up Telerhythmics, a provider of 24-hour cardiac monitoring services, in a deal worth at least $3.6 million. Story

> CorTechs Labs nailed down a new Series B investment intended to accelerate the development of its image analysis medical software and also boost sales/marketing efforts. Release

Biotech News

@FierceBiotech: AstraZeneca signs up for MD Anderson's 'moon-shot' immuno-oncology project. More | Follow @FierceBiotech

@JohnCFierce: Upbeat review of failed PhII DMD trial earns Prosensa a big boost to shares. News | Follow @JohnCFierce

@DamianFierce: A quarter of European doctors can't define biosimilars. Story via Bloomberg. | Follow @DamianFierce

@EmilyMFierce: Snails and quails in today's issue of FierceBiotech Research. | Follow @EmilyMFierce

> Meet RestorGenex, a biotech mosaic from Celgene founder Barer. News

> Eager biotechs eye $133M in IPOs as a frenzied quarter closes. Article

Pharma News

@FiercePharma: Best-read special report over the weekend: Top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Story | Follow @TracyStaton

@EricPFierce: New purification plant is part of Novo Nordisk 's $3.7B R&D push. News | Follow @EricPFierce

@CarlyHFierce: Going to check out South America for a few days. Talk to you Thursday, Twitterverse! | Follow @CarlyHFierce

> Pfizer sues India's Torrent in latest bid to fend off generic Viagra. News

> Why is ThromboGenics' strategic review urgent? Just look at recent Jetrea sales. More

> New incontinence data could give Ipsen's Dysport a path to lucrative urology use. Story

Biotech Research News

> Capturing leukemic stem cells may help propel new drug discovery. More

> Study: Chickens, quails are likely to blame for spread of H7N9. Piece

> Drug derived from snail venom could treat chronic pain with fewer side effects. Article

> Compound stops formation of toxic peptides in mice with Alzheimer's. More

> NIH cuts, sequestration hampering cancer research. Story

> Stem cell therapy improves tendon healing in preclinical study. Item

Pharma Manufacturing News

> Japan's Eisai intends to nearly triple production to 2 billion tablets at its plant in Vizag, India. Report

> The FDA has added two Chinese drug manufacturing facilities to its list of banned plants. Alerts

> India's Supreme Court ruled in favor of a public interest investigation into whether Ranbaxy Laboratories supplied adulterated drugs in the country. Report

> Ranbaxy Laboratories insists the drugs it sells in India are safe and effective. Story

> Optel Visions is expanding its inspection systems offerings. Release

Suggested Articles

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.

The dream of a comfortable, tabletop blood testing device, needing only a few drops taken from a finger and a handful of minutes, has now arrived.

Novartis is now teaming up with Amazon’s mammoth cloud computing division to overhaul its manufacturing, supply and business operations.